The retaliatory measures followed Trump's controversial move to order the withdrawal of all U.S. troops from Syria's northern border with Turkey.Politicsread more
Bloomberg could be in for a showdown with Elizabeth Warren, whether he runs or not.2020 Electionsread more
As the season kicks into gear this week, S&P 500 firms are expected to report a 4.6% earnings decline over the same period a year agoEarningsread more
"I think that may have scared the Chinese that they were going to get into a serious trade war with access to our capital markets being cut off, among other things," Michael...China Politicsread more
David Rolfe, a longtime Berkshire Hathaway shareholder and CIO at Wedgewood Partners, is fed up with Warren Buffett.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Wall Street analysts estimate GM has lost more than $1 billion due to the United Auto Workers' strike, which began Sept. 16.Autosread more
Top financial companies will mark the unofficial start of earnings season with their reports this week, and experts are offering several recommendations for trading the moves.ETF Edgeread more
The indexes traded in a tight range as investors looked ahead to the start of the earnings season while grappling with new worries over trade.Marketsread more
The union that represents Southwest Airlines pilots don't expect the grounded Boeing 737 Max to return until at least February, about a month later than the airline expects.Airlinesread more
Check out the companies making headlines in midday trading:Market Insiderread more
-spokeswoman@ (Adds context about Meridian's relationship with EpiPen)
July 29 (Reuters) - Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it is creating by combining its older off-patent medicines unit with Mylan NV , a Pfizer spokeswoman said.
The discussions on the arrangement are still ongoing and there is no guarantee that a deal will be reached, but the parties are aiming to reach a final decision before the close of the larger Pfizer-Mylan deal in 2020, Pfizer said.
Merging Meridian into the spun-off business could potentially help it cope with ongoing shortages of one of Mylan's flagship products, EpiPen, an epinephrine injector used for treating severe allergic reactions.
Meridian, which produces all EpiPens sold globally at a single plant near St. Louis, has been hit by a series of manufacturing problems. The company said in early July it anticipates further supply shortages over the coming months.
There is traditionally high demand for the devices in the summer as families look to renew prescriptions ahead of sending children to summer camp or the new school year.
Mylan, a generic drugmaker, has been facing new competition for the emergency allergy treatment. Teva Pharmaceuticals Industries (TEVA.TA> has launched its own EpiPen rival product, and other companies including Novartis AG, Kaleo Inc and Amneal Pharmaceuticals Inc. also are in the market. (Reporting by Carl O'Donnell and Tamara Manias in Bengalaru Editing by Paul Simao Editing by Bill Berkrot)